NCT

Starting in 2027, Captain T Cell – a Max Delbrück Center biotech spin-off – will begin the first clinical trial of its TCR-T cell therapy. This has been made possible through funding from the National Center for Tumor Diseases and close collaboration with Charité – Universitätsmedizin Berlin.

From 2024, the Federal Government and the State of Berlin will fund the establishment of the National Center for Tumor Diseases (NCT) Berlin. The new site is a cooperation between DKFZ and Charité, BIH, and Max Delbrück Center aimed at closely integrating clinical and translational cancer research.